KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT07260812
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Hodgkin Lymphoma
Diffuse Large B Cell Lymphoma (DLBCL)
Interventions
DRUG:
KSV01 Injection
Sponsor
TCRx Therapeutics Co.Ltd
Collaborators
[object Object]